Chemotherapy characteristics
. | . | . | . | Dose, mg/m2/d or mg/d†(days of administration in each cycle) . | . | . | . | . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regimen . | Patients (WBC measurements) . | Age . | Cycles (cycle duration, d) . | CPH . | DOX . | VIN . | ETO . | PRO . | BLM . | PRD . | G-CSF* . | |||||||
| CHOP-21‡ | 396 (8055) | y/o | 6 (21) | 750 (1) | 50 (1) | 2† (1) | None | None | None | 100† (1-5) | None | |||||||
| CHOP-14‡ | 393 (8354) | y/o | 6 (14) | 750 (1) | 50 (1) | 2† (1) | None | None | None | 100† (1-5) | (4-13) | |||||||
| CHOEP-21‡ | 387 (9071) | y/o | 6 (21) | 750 (1) | 50 (1) | 2† (1) | 100 (1-3) | None | None | 100† (1-5) | None | |||||||
| CHOEP-14‡ | 398 (9335) | y/o | 6 (14) | 750 (1) | 50 (1) | 2† (1) | 100 (1-3) | None | None | 100† (1-5) | (4-13) | |||||||
| CHOP-14s, with shortened G-CSF‡ | 374 (7029) | o | 6/8 (14) | 750 (1) | 50 (1) | 2† (1) | None | None | None | 100† (1-5) | (6-12) | |||||||
| hCHOEP-21‡ | 79 (2824) | y | ||||||||||||||||
| Dose level 1 | 6 (21) | 1000 (1) | 27.5 (1) | 2† (1) | 125 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 2 | 6 (21) | 1200 (1) | 30.0 (1) | 2† (1) | 150 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 3 | 6 (21) | 1400 (1) | 32.5 (1) | 2† (1) | 175 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 4 | 6 (21) | 1600 (1) | 35.0 (1) | 2† (1) | 200 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| hCHOEP-14‡ | 39 (1332) | y | ||||||||||||||||
| Dose level 1 | 6 (14) | 1000 (1) | 27.5 (1) | 2† (1) | 125 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 2 | 6 (14) | 1200 (1) | 30.0 (1) | 2† (1) | 150 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| BEACOPP-21-baseline§ | 430 (11 789) | y | 8 (21) | 650 (1) | 25 (1) | 2† (8) | 100 (1-3) | 100 (1-7) | 10 (8) | 100 (1-14) | None | |||||||
| BEACOPP-21-escalated§ | 399 (15 840) | y | 8 (21) | 1250 (1) | 35 (1) | 2† (8) | 200 (1-3) | 100 (1-7) | 10 (8) | 100 (1-14) | (8-15) | |||||||
| BEACOPP-14§ | 82 (1969) | y | 8 (14) | 650 (1) | 25 (1) | 2† (8) | 100 (1-3) | 100 (1-7) | 10 (8) | 80 (1-7) | (8-13) | |||||||
. | . | . | . | Dose, mg/m2/d or mg/d†(days of administration in each cycle) . | . | . | . | . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regimen . | Patients (WBC measurements) . | Age . | Cycles (cycle duration, d) . | CPH . | DOX . | VIN . | ETO . | PRO . | BLM . | PRD . | G-CSF* . | |||||||
| CHOP-21‡ | 396 (8055) | y/o | 6 (21) | 750 (1) | 50 (1) | 2† (1) | None | None | None | 100† (1-5) | None | |||||||
| CHOP-14‡ | 393 (8354) | y/o | 6 (14) | 750 (1) | 50 (1) | 2† (1) | None | None | None | 100† (1-5) | (4-13) | |||||||
| CHOEP-21‡ | 387 (9071) | y/o | 6 (21) | 750 (1) | 50 (1) | 2† (1) | 100 (1-3) | None | None | 100† (1-5) | None | |||||||
| CHOEP-14‡ | 398 (9335) | y/o | 6 (14) | 750 (1) | 50 (1) | 2† (1) | 100 (1-3) | None | None | 100† (1-5) | (4-13) | |||||||
| CHOP-14s, with shortened G-CSF‡ | 374 (7029) | o | 6/8 (14) | 750 (1) | 50 (1) | 2† (1) | None | None | None | 100† (1-5) | (6-12) | |||||||
| hCHOEP-21‡ | 79 (2824) | y | ||||||||||||||||
| Dose level 1 | 6 (21) | 1000 (1) | 27.5 (1) | 2† (1) | 125 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 2 | 6 (21) | 1200 (1) | 30.0 (1) | 2† (1) | 150 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 3 | 6 (21) | 1400 (1) | 32.5 (1) | 2† (1) | 175 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 4 | 6 (21) | 1600 (1) | 35.0 (1) | 2† (1) | 200 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| hCHOEP-14‡ | 39 (1332) | y | ||||||||||||||||
| Dose level 1 | 6 (14) | 1000 (1) | 27.5 (1) | 2† (1) | 125 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| Dose level 2 | 6 (14) | 1200 (1) | 30.0 (1) | 2† (1) | 150 (1-3) | None | None | 100† (1-5) | (6-13) | |||||||||
| BEACOPP-21-baseline§ | 430 (11 789) | y | 8 (21) | 650 (1) | 25 (1) | 2† (8) | 100 (1-3) | 100 (1-7) | 10 (8) | 100 (1-14) | None | |||||||
| BEACOPP-21-escalated§ | 399 (15 840) | y | 8 (21) | 1250 (1) | 35 (1) | 2† (8) | 200 (1-3) | 100 (1-7) | 10 (8) | 100 (1-14) | (8-15) | |||||||
| BEACOPP-14§ | 82 (1969) | y | 8 (14) | 650 (1) | 25 (1) | 2† (8) | 100 (1-3) | 100 (1-7) | 10 (8) | 80 (1-7) | (8-13) | |||||||
CPH indicates cyclophosphamide; DOX, doxorubicin; VIN, vincristine, ETO, etoposide; PRO, procarbazine; BLM, bleomycin; PRD, prednisone; G-CSF, granulocyte colony-stimulating factor; y, young (younger than 60 years); and o, old (60 years or older).
Subcutaneous administration, 300 or 480 μg/d (depending on body weight).
Doses expressed as mg/d are marked with a dagger.
Part of a trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Part of a trial of the German Hodgkin's Lymphoma Study Group.